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Abstract Systematic collection of phenotypes and their 
correlation with molecular data has been proposed as a 
useful method to advance in the study of disease. Although 
some databases for animal species are being developed, 
progress in humans is slow, probably due to the multifacto-
rial origin of many human diseases and to the intricacy of 
accurately classifying phenotypes, among other factors. 
An alternative approach has been to identify and to study 
individuals or families with very characteristic, clinically 
relevant phenotypes. This strategy has shown increased ef-
fi ciency to identify the molecular features underlying such 
phenotypes. While on most occasions the subjects selected 
for these studies presented harmful phenotypes, a few stud-
ies have been performed in individuals with very favour-
able phenotypes. The consistent results achieved suggest 
that it seems logical to further develop this strategy as a 
methodology to study human disease, including cancer. 
The identifi cation and the study with high-throughput tech-
niques of individuals showing a markedly decreased risk of 
developing cancer or of cancer patients presenting either 
an unusually favourable prognosis or striking responses 
following a specifi c treatment, might be promising ways to 
maximize the yield of this approach and to reveal the mo-
lecular causes that explain those phenotypes and thus high-
light useful therapeutic targets. This manuscript reviews the 
current status of selection of extreme phenotypes in cancer 
research and provides directions for future development of 
this methodology.
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Introduction
Despite the fact that human beings share the vast majority 
of their genetic information, the few remaining variations 
account for an astonishingly wide range of different phe-
notypes. The importance of characterizing such differences 
is widely recognized by the scientific community and 
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enormous efforts are being made to understand their role in 
disease [1]. Indeed, a useful method to advance in this path 
has been to correlate molecular data with phenotypes. The 
soundness of this strategy is straightforward and the devel-
opment of phenotype databases has already been proposed 
[2, 3]. Yet, although such databases are being generated for 
species such as yeasts [4] or rodents [5, 6] and are under 
development for human beings [7, 8], progress is proceed-
ing at a relatively slow pace due to the enormous complex-
ity of this task, which is at least in part caused by the mul-
tifactorial origin of many diseases and by the intricacy of 
accurately classifying phenotypes.
In the meanwhile, a frequent approach has been to cor-
relate molecular features in groups of patients with their 
phenotypes, expressed as clinical variables, such as prog-
nosis or treatment effects. Some relevant examples of the 
use of this strategy in oncology are the correlation between 
thymidylate synthase expression and effi cacy of 5-fl uorou-
racil in digestive tumours [9]; or the identifi cation of gene-
expression profi les of prognostic value in lymphoma [10] 
or breast cancer patients [11]. However, despite the sig-
nifi cance of some results, the conclusions reached by many 
studies are of uncertain clinical signifi cance or even contra-
dictory [12]. This has led to the establishment of specifi c 
guidelines to validate conclusions before their publication 
[12–14]. Several factors may cause these biases, including 
methodological issues, such as retrospective data collec-
tion, limitations in laboratory techniques or the biology of 
complex diseases [12, 15], such as cancer, which present 
multiplex phenotypes. In addition, classifi cation of patients 
into subgroups with good or bad evolution that present 
moderate differences, such as subtle improvements in sur-
vival, from one to the other may lead to the identifi cation 
of molecular features associated with modest differences of 
borderline clinical relevance.
A useful and intuitive approach to circumvent some of 
these problems has been to select individuals with very char-
acteristic, clinically relevant phenotypes and to study the un-
derlying causes. This strategy assumes that these patients are 
the most informative and thus should be studied separately, 
rather than being included in larger series of patients that 
might dissipate the information that they can provide. Even 
though this strategy has allowed the identifi cation of relevant 
biological facts with great effectiveness, through the study 
of reduced numbers of subjects, and has been proposed as a 
methodology for the study of human disease [16–20], its use 
has not become widespread. This manuscript reviews the cur-
rent status of extreme phenotype selection in cancer research 
and provides relevant examples that support its value, along 
with potential directions to further develop this strategy.
Selection of apparent phenotypes
Apparent phenotypes present characteristic attributes and 
therefore can be identifi ed by observation. Sometimes the 
phenotype is readily recognized, because its characteristics 
are obvious. This is the case of the widely employed strat-
egy of identifying gene mutations that cause genetically 
inherited diseases [21]. Paradigmatic examples in oncol-
ogy include syndromes characterized by the development 
of multiple tumours, such as multiple endocrine neoplasia, 
type 1 (MEN-1). The description of parathyroid, pancre-
atic and pituitary tumours in autopsies of patients with 
acromegaly [22], and its familial association [23, 24] pre-
ceded by decades the identifi cation of the MEN-1 tumour-
suppressor oncogene [25] and its mutations in affected 
individuals [26]. Another outstanding example is the detec-
tion of mutations in BRCA-1, a gene that was identifi ed 
in families that presented a high incidence of early-onset 
breast carcinoma [27]. 
On other occasions the phenotypes are less evident 
and complex epidemiological studies are required to iden-
tify them. An illustrative example is the Li-Fraumeni syn-
drome, described through the identifi cation of an increased 
incidence of rhabdomyosarcomas in siblings following the 
review of over 20,000 children’s death certifi cates [28, 29]. 
As in the previous example, the identifi cation of the pheno-
type allowed the hypothesis to be formulated that eventu-
ally led to the detection of germ-line p53 mutations as the 
cause [30].
Finally, sometimes characteristic phenotypes are ex-
pressed only under certain circumstances, such as after 
treatment administration. For example, the description of 
severe toxicity after 5-fl uorouracil administration [31] al-
lowed the identifi cation of the biochemical [32] as well as 
the genetic underlying causes [33]. Another relevant exam-
ple is the discovery of the expression of epidermal growth 
factor receptor (EGFR) mutations in tumours of patients 
responding to EGFR tyrosine-kinase inhibitors [34, 35]. 
Paradoxically, in this setting the study of a relatively low 
number of subjects yielded very relevant and clinically use-
ful results, in contrast to the modest conclusions obtained 
after studying thousands of patients through conventional 
randomized trials [36–39], which assume that the benefi t 
that the treatment produces only in a group of patients is 
large enough to administer it to the whole unselected popu-
lation. Interestingly, the selection and study of patients 
with extreme responses (most vs. least sensitive), extreme 
drug metabolisms (high vs. low) or extreme toxic effects 
(no toxicity at high doses vs. high toxicity at low doses) 
following drug therapy has been described by Nebert as a 
well defi ned methodology in clinical pharmacology, in a 
manuscript that reviews studies in which this strategy has 
been successfully employed [16]. The same author and his 
collaborators have also described in detail the statistical 
rationale that supports this methodology [40]. 
The common factor underlying all these examples is 
that the initial step was the identifi cation of the characteris-
tic phenotypes. Subsequent study of the selected individu-
als led to the identifi cation of the molecular causes. The ef-
fectiveness of this strategy is notable, because the number 
of subjects that need to be studied is relatively small. In ad-
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dition, the clinical relevance is high, because the attributes 
of the selected phenotypes are signifi cant. Therefore, we 
believe that this methodology should be further developed 
in cancer research. Relevant case-selection should include 
cancer patients with very characteristic and uncommon 
evolution. Currently, many advanced solid tumours are 
considered incurable and result in short survival. Nonethe-
less, clinical experience shows that exceptions exist even 
among the malignancies presenting the direst prognosis, 
and every oncologist treats patients that are unexpectedly 
cured or that live far beyond their estimated prognosis. 
Even though many of those cases are not published, some 
reports of long-term survivors of apparently incurable tu-
mours such as pancreatic cancer [41, 42], gastric cancer 
[43–46], colon cancer [47], small [48, 49] and non-small-
cell lung cancer [50, 51] or multiple myeloma [52] can be 
found in the medical literature. Assuming that the diag-
nostic and staging work-up has been correctly performed, 
these individuals may represent extreme phenotypes wor-
thy of detailed study. Similarly, patients presenting early-
stage cancer that receive adequate treatment and that either 
do not relapse despite presenting a high risk of recurrence 
or relapse despite a very low risk of recurrence, might be 
interesting groups to study. A clinical example of the for-
mer design would be to study patients with T1G3 bladder 
tumours that do not relapse and patients that present low-
grade papillary tumours that recur following adequate local 
treatment. Patients showing extreme responses or toxic 
effects to a given treatment, as suggested by Nebert [16], 
also constitute interesting phenotypes to identify and to 
study. In fact, this methodological design deserves further 
consideration in the current scenario in which hundreds of 
drugs are being developed, but only a few obtain regulatory 
approval, based on conventional drug development meth-
odology. Further development of multiple drugs might be 
of clinical interest, even if they just show clinical activity 
in a limited subgroup of patients, assuming that it would be 
possible to identify such patients. Studies in which patients 
receive a treatment in a non-randomized fashion and those 
patients that present marked benefi t are intensively stud-
ied to elucidate specifi c markers of activity might become 
complementary to current randomized studies. The sample 
size of these studies should allow to identify a suffi cient 
number of patients presenting clear benefi t from the treat-
ment. Such studies might become a useful tool to further 
develop personalized medicine, allowing identifi cation of 
those patients that achieve a truly signifi cant benefi t from a 
specifi c treatment.
Fig. 1 Flow chart representing the process from selection of extreme phenotypes to determination of 
their molecular causes. Although the observation of extreme phenotypes clearly suggests that there is 
indeed a needle in the haystack to fi nd, it offers limited clues about the nature of the causative mecha-
nisms. Nonetheless, limiting the number of cases and tissue samples to analyze provides a considerable 
degree of simplicity that to date has been largely neglected. Initial screening of factors that might explain 
the phenotypes might be performed either by studying specifi c major molecular pathways or applying 
high throughput techniques. Once these potential clues have been identifi ed, the specifi c underlying 
mechanisms should be addressed in detail
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Multiple potential causes might explain these pheno-
types, and they could be related to host and tumour fac-
tors as well as environmental causes (Fig. 1). Host factors 
might include regulation of immune response, angiogen-
esis, apoptosis or DNA repair mechanisms, ability to con-
trol metastasis or advantageous metabolism of anti-cancer 
treatments, among others. Tumour factors might comprise 
abnormalities in drug or immune resistance, cell cycle and 
apoptosis regulation, and so on. Since multiple hypotheses 
should be studied, the assessment of specifi c major molec-
ular pathways and the use of high-throughput techniques, 
which allow the simultaneous assessment of multiple bio-
logical factors, seem necessary. Even though the interpreta-
tions of these techniques is somewhat cumbersome, due to 
the large amount of information they produce, the use of a 
reduced sample population that present marked and clini-
cally relevant characteristics should clearly improve the 
effi ciency of such studies.
This strategy has already been followed by some re-
searchers. The study of melanoma patients with long-
term survival has highlighted tumour immune escape as 
a mechanism of disease progression and shifting of T-cell 
responses as a response to this escape [53], as well as pro-
longed persistence of specifi c CD8+ cells as a potential 
cause of maintenance of long disease remissions [54, 55]. 
Interestingly, all these observations, which support the 
concepts of cancer immunosurveillance and immunoedit-
ing [56], were obtained from the study of just 4 patients. 
We have used this strategy in renal cell carcinoma patients 
treated with the antiangiogenic drug sunitinib. Sera from 
3 patients showing marked responses and from 3 patients 
that presented clear progressions were analyzed with a Hu-
man Cytokine Array, which evaluates 174 cytokines. We 
identifi ed 27 cytokines, which varied signifi cantly between 
both groups, and we further selected and assessed the most 
relevant cytokines by ELISA in 21 evaluable patients, 
concluding that TNF- and MMP-9 baseline levels were 
predictive of response [57]. In a similar study performed 
in melanoma and renal cell-carcinoma patients, vascular 
endothelial growth factor and fi bronectin were identifi ed as 
predictors of response to high dose intravenous IL-2 [58]. 
Although these studies warrant confi rmation, they support 
the relevance of selection of patients with extreme pheno-
types and their study with high-throughput techniques as 
a valid method to identify candidate predictive factors of 
drug activity.
Selection of non-apparent phenotypes
Non-apparent phenotypes are those not associated with 
characteristic attributes and therefore they cannot be identi-
fi ed by mere observation. An example is the existence of 
protection against developing a disease. Since one specifi c 
disease does not develop in the majority of individuals, the 
existence of protection cannot be distinguished from the 
simple absence of disease by chance, unless the risk of de-
veloping that disease is taken into consideration.
It is well known that cancer incidence under similar 
environmental conditions is not uniform. If cancer risk fol-
lowed a normal distribution, as most biological variables 
do, we could hypothesize that just as some individuals 
present an increased incidence, other subjects may have 
lower incidence than expected. If these individuals exist, 
it would be naïve to attribute their phenotype to chance, 
at least until other causes have been ruled out, and their 
identification and study could increase our knowledge 
about cancer and yield useful therapeutic targets. This 
protection could be secondary to many factors, including 
specifi c mechanisms of DNA repair, cell cycle regulation, 
metabolism of carcinogens, angiogenesis, apoptosis or im-
munological response among others (Fig. 1). 
Although it seems reasonable that selection of individu-
als presenting decreased risk of developing cancer might 
have been favoured by evolution to a certain extent, the 
question remains if such subjects do really exist. Looking 
to other diseases, we can fi nd relevant examples, some of 
which have been successfully identified through selec-
tion of extreme phenotypes. One outstanding paradigm is 
the identifi cation of alterations in the gene encoding the 
chemokine coreceptor CCR5 that confer complete protec-
tion against certain strains of the human immunodefi ciency 
virus (HIV) [59, 60]. Since CCR5 mutations were not asso-
ciated with phenotypic abnormalities, they were only iden-
tifi ed after observing that some individuals highly exposed 
to HIV never developed the infection [61]. The study of 
those individuals allowed the discovery of a relevant target 
in HIV investigation. 
Returning to cancer, some preclinical studies sup-
port the biological plausibility of the existence of protec-
tive mechanisms. A relevant example is the creation of a 
“super-p53” mouse, carrying supernumerary p53 copies, 
which shows a decreased risk of developing chemically 
induced tumours [62]. Although these mice and other simi-
lar models [63, 64] have been artifi cially developed, their 
relatively normal phenotypes raise the question of whether 
similar phenomena could spontaneously occur and be 
selected for in nature. It is known that small malignant 
tumours identifi ed in autopsies or by high-performance im-
aging tests outnumber the quantity of clinically overt can-
cers [65]. However, it is unknown whether this is caused by 
protective mechanisms or if it is due to other reasons, such 
as differences in tumour biology. The same questions arise 
when we analyse the different sensitivity of individuals to 
carcinogens such as tobacco or the variations in clinical 
aggressiveness of tumours in different patients: while large 
differences exist, it is diffi cult to establish their causes.
Even if we assume that individuals bearing protection 
against developing cancer may exist, the question of how 
to identify them remains. Several studies have assessed the 
protective role of enzymatic polymorphisms with inconclu-
sive results, as reviewed elsewhere [18]. Most compared 
cancer patients with normal individuals. Such a design 
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offers the disadvantage that, rather than true protection 
against cancer, normal subjects may just present absence of 
disease with a normal risk of developing it. Instead, protec-
tion can be expected in individuals not developing cancer 
despite presenting an increased risk. This approach has 
been successfully evaluated in the study of polymorphisms 
of detoxifying enzymes, using elderly individuals not pre-
senting cancer as controls, sometimes even when they were 
smokers [66–69]. While these studies truly select extreme 
phenotypes, their design could be improved by the use of 
high-throughput techniques, which study multiple potential 
causes, rather than just a few; and by selecting individuals 
with even more characteristic phenotypes, i.e., a markedly 
reduced individual or familial risk of developing cancer. 
Families presenting very low cancer incidence across sev-
eral generations might show reduced familial risk. Subjects 
with high-risk cancer factors, such as extensive exposure 
to carcinogens or cancer familial syndromes that do not 
develop the disease, or in whom development is signifi -
cantly delayed, may present reduced individual risk. Some 
sensitive models that have already been proposed might 
be familial adenomatous polyposis [18] or hereditary non-
polyposis colorectal cancer [70], because they present high 
penetrance and, therefore, the likelihood that an affected 
individual will not develop cancer is low. The study of 
heavy smokers that do not develop cancer at an advanced 
age and of young smokers who develop the disease might 
also yield relevant information on cancer protective mecha-
nisms and tumour development and growth. Different 
combinations of these strategies could be developed. Ag-
gregation of similar phenotypes within one family would 
further support that their underlying cause is not random. 
Theoretically, the likelihood of fi nding clinically relevant 
results should be directly related to the magnitude of the 
discrepancy between the estimated risk of presenting can-
cer and the observed phenotype. 
Conclusions and future directions
Extreme phenotype selection is a well defi ned biological 
concept that describes how environmental pressures favour, 
among traits exhibiting diverse phenotypes, the fi ttest to 
overcome the hazards encountered. Although it seems 
logical to study the favoured phenotypes to determine their 
mechanisms of success, the use of this strategy has often 
been restricted to obvious cases or to isolated observations 
made by discerning clinicians. The lack of a systematic ap-
proach to the identifi cation of extreme phenotypes is what 
has probably precluded most of them from being studied. 
Therefore, a consistent methodology should be developed 
to maximize the potential benefi t of this strategy. Specifi -
cally in the fi eld of oncology, we propose the creation of 
databases compiling patient samples, together with clini-
cal and epidemiological data from individuals presenting 
relevant phenotypes. The collection and intensive study of 
these extreme cases, rather than constituting a mere list of 
oddities, might provide excellent hunting grounds to dis-
cover Achilles heels of cancer.
This methodology does, however, raise some issues. 
Principal among these are the questions of how to classify 
phenotypes into quantitative groups [16] in order to defi ne 
what constitutes an extreme phenotype, and how to iden-
tify them. Defi nition of phenotypes that might be clinically 
relevant and that can be found in clinical practice should 
probably be performed by consensus panels of experienced 
clinicians under the coordination of medical societies or 
cooperative groups. Case selection should be approached 
by training and creating awareness among medical special-
ists. Cancer patients with very favourable evolution, or with 
extreme responses or toxicities following therapy could be 
selected in oncology centres relatively easily, since their 
number is small and their characteristics are unusual. Indi-
viduals presenting cancer familial syndromes not develop-
ing cancer despite their high risk could be selected through 
genetic counselling units. In other cases, more complex 
epidemiological studies might be required to identify rel-
evant discordances between the expected and the observed 
phenotypes. Since it is unlikely that an adequate number 
of subjects bearing extreme phenotypes can be detected in 
a limited number of institutions, this will require the col-
laboration of large cooperative groups, ideally at an inter-
national level.
Another issue is what variables should be studied in 
these subjects. Characteristic phenotypes may be caused 
by host or tumour factors, as well as by external causes. 
Therefore, all of these should be analyzed, and ideally 
samples from the tumour and from the host’s normal tissue 
should be collected, along with clinical and epidemiologi-
cal data. The type and quantity of the samples should allow 
a wide variety of studies to be performed, including screen-
ing of cell genomes, epigenomic changes and transcrip-
tomes through high-throughput techniques, as mentioned 
above, such as Genome Wide Association Studies (GWAS) 
or full genome sequencing. The samples should also per-
mit additional studies to be performed in the future using 
techniques that are not yet available. At a minimum, whole 
blood, including serum and DNA and, in the case of cancer 
patients, fresh and paraffi n-embedded tumour tissue, should 
be collected. Even though this methodology does not avoid 
the inherent problems of sample collection, it does dra-
matically limit the number of samples to be obtained and 
studied. Unavailability of samples might be an important 
limitation, which could be overcome by prospective collec-
tion of cases. The importance of an adequate infrastructure 
to collect and store samples and to manage the database 
cannot be overemphasized. Lastly, ethical issues may be 
another point of concern, since the use of biologic material 
is subject to strict regulations. Ethical boards must collabo-
rate to make these studies feasible without compromising 
the rights of the participants. The possibility of contacting 
subjects in order to obtain more information or to perform 
functional studies should be taken into consideration. Well 
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designed informed consent processes and prospective data 
collection should minimize these problems. 
In conclusion, the selection and the study of extreme, 
clinically relevant phenotypes is an effi cient strategy to 
identify their underlying causes. The creation of collabora-
tive databases compiling biological samples and clinical in-
formation from such phenotypes might increase our knowl-
edge of cancer and provide new therapeutic strategies. This 
will require close and continued collaboration between 
clinicians, who must identify appropriate cases, and basic 
scientists, who should perform adequate studies to identify 
and integrate the relevant targets. Even in the current age 
of modern molecular biology, clinical observation should 
remain a preferred strategy to generate hypothesis than in-
tellectual speculation.
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